

Prof. Dr. med. Oliver Pfaar, Philipps-Universität Marburg, Germany, has been appointed as Vice President of Communications of the European Academy of Allergy and Clinical Immunology (EAACI) on June 3, 2024.

The [European Academy of Allergy and Clinical Immunology \(EAACI\)](#) held its annual congress from May 31 to June 3, 2024, in the vibrant city of Valencia, Spain. This year's congress, under the inspiring motto "Revolutionising Patient Care through the Power of Data Science," marked a significant milestone in the field of allergy and clinical immunology, showcasing groundbreaking advancements and fostering global collaboration.

The congress featured more than 150 scientific sessions, providing a comprehensive platform for disseminating cutting-edge research and innovative clinical practices. Attendees, ranging from seasoned experts to emerging scientists, engaged in a dynamic exchange of knowledge and ideas, reflecting the vibrant and collaborative spirit of the EAACI community.

Renowned experts from various corners of the world shared their invaluable insights, experiences, and the latest innovations in several key areas. The congress's scientific program covered a wide array of topics, including Precision and Personalised Medicine, Artificial Intelligence and Data Science, Allergen Immunotherapy and Immune Modulators, Biologicals and Novel Treatments in Allergy and Asthma, Prevention of Allergic Diseases, and Innovation in Clinical Trials or One Health.



A significant highlight of the EAACI Congress 2024 was the election of the new [Executive Committee](#). This election brought fresh perspectives to the EAACI leadership, ensuring continued progress and innovation in the field. Among the newly elected members, Professor Oliver Pfaar (Germany) was appointed as the Vice President of Communications. His extensive experience and expertise are expected to enhance EAACI's communication strategies and outreach, fostering greater engagement within the allergy and immunology community.

As the congress concluded, attendees departed with renewed enthusiasm and a shared commitment to advancing patient care through scientific innovation and global cooperation. The EAACI Congress 2024 in Valencia will be remembered as a landmark event, setting the stage for a future where data science and personalised medicine transform the landscape of allergy and clinical immunology.

About EAACI

The European Academy of Allergy and Clinical Immunology (EAACI) is the primary source of expertise in Europe for all aspects of allergy. EAACI is an association comprising clinicians, researchers, and allied health professionals dedicated to improving the health of individuals affected by allergic diseases. With over 16,000 members from 125 countries and over 50 National Allergy Societies, EAACI represents a global network committed to advancing research, education, and clinical practice in allergy and clinical immunology.

For more information, visit the EAACI website at www.eaaci.org.